Citadel Advisors
NAVB

Citadel Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Citadel Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-65,807
Closed -$17.1K – 15791
2023
Q1 		$17.1K Sell
65,807
-28,042
-30% -$8.19K ﹤0.01% 13170
2022
Q4 		$19.7K Buy
+93,849
New +$23.5K ﹤0.01% 13154
2022
Q3 		– Sell
-24,217
Closed -$11.3K – 14317
2022
Q2 		$17K Buy
24,217
+6,655
+38% +$5.65K ﹤0.01% 12473
2022
Q1 		$14K Sell
17,562
-41,000
-70% -$37.6K ﹤0.01% 13342
2021
Q4 		$59K Buy
58,562
+16,425
+39% +$23.1K ﹤0.01% 13162
2021
Q3 		$74K Sell
42,137
-22,506
-35% -$37.9K ﹤0.01% 13128
2021
Q2 		$118K Buy
64,643
+10,129
+19% +$17.9K ﹤0.01% 12771
2021
Q1 		$110K Buy
54,514
+37,219
+215% +$87.1K ﹤0.01% 12399
2020
Q4 		$37K Sell
17,295
-9,197
-35% -$21.7K ﹤0.01% 10673
2020
Q3 		$72K Sell
26,492
-4,106
-13% -$14.7K ﹤0.01% 9454
2020
Q2 		$121K Buy
30,598
+2,471
+9% +$4.73K ﹤0.01% 8884
2020
Q1 		$21K Buy
+28,127
New +$31K ﹤0.01% 9297
2019
Q4 		– Sell
-28,915
Closed -$20K – 10237
2019
Q3 		$20K Buy
28,915
+12,146
+72% +$7.47K ﹤0.01% 8947
2019
Q2 		$11K Buy
16,769
+4,168
+33% +$8.08K ﹤0.01% 9032
2019
Q1 		$35K Buy
12,601
+6,126
+95% +$18.1K ﹤0.01% 8957
2018
Q4 		$13K Sell
6,475
-220
-3% -$907 ﹤0.01% 8887
2018
Q3 		$31K Sell
6,695
-2,412
-26% -$9.14K ﹤0.01% 8928
2018
Q2 		$42K Buy
9,107
+300
+3% +$1.57K ﹤0.01% 8477
2018
Q1 		$63K Buy
8,807
+3,117
+55% +$23.3K ﹤0.01% 7861
2017
Q4 		$41K Buy
5,690
+3,656
+180% +$30.9K ﹤0.01% 7686
2017
Q3 		$17K Buy
2,034
+506
+33% +$4.29K ﹤0.01% 7392
2017
Q2 		$16K Buy
1,528
+58
+4% +$573 ﹤0.01% 7339
2017
Q1 		$17K Buy
+1,470
New +$16.7K ﹤0.01% 7299
2016
Q4 		– Sell
-3,426
Closed -$63K – 8179
2016
Q3 		$63K Buy
3,426
+2,740
+399% +$34.7K ﹤0.01% 6799
2016
Q2 		$7K Buy
686
+72
+12% +$1.41K ﹤0.01% 6745
2016
Q1 		$12K Sell
614
-1,338
-69% -$25.7K ﹤0.01% 6582
2015
Q4 		$52K Buy
1,952
+616
+46% +$21.4K ﹤0.01% 7284
2015
Q3 		$61K Buy
+1,336
New +$50.4K ﹤0.01% 7432
2015
Q1 		– Sell
-4,711
Closed -$178K – 9013
2014
Q4 		$178K Buy
4,711
+4,122
+700% +$113K ﹤0.01% 6108
2014
Q3 		$16K Sell
589
-46
-7% -$1.22K ﹤0.01% 7598
2014
Q2 		$19K Buy
635
+614
+2,924% +$19.9K ﹤0.01% 7324
2014
Q1 		$1K Sell
21
-2,253
-99% -$85.5K ﹤0.01% 7781
2013
Q4 		$94K Buy
2,274
+944
+71% +$36.9K ﹤0.01% 5661
2013
Q3 		$70K Buy
1,330
+1,089
+452% +$63.5K ﹤0.01% 5587
2013
Q2 		$13K Buy
+241
New +$12K ﹤0.01% 6182

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Citadel Advisors's NAVB Position: Q2 2023 in Review

Citadel Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 65,807 shares — an estimated $17.1K sold.

Citadel Advisors first reported a position in NAVB in Q2 2013 and held it in 35 quarters. The position peaked at $178K in Q4 2014. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Citadel Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 65,807 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $17.1K.
  • Citadel Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 35 quarters.
  • Citadel Advisors's Navidea Biopharmaceuticals Inc. position peaked at $178K in Q4 2014.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.